Kaipio K, Chen P, Roering P, et al. - Tissue and ascites samples, treatment-naive and/or following neoadjuvant chemotherapy, were prospectively obtained to characterize stemness characteristics in primary patient-derived cell lines, associate stemness markers with clinical outcome, and examine the response of the cells to both conventional and exploratory drugs. The investigators identified stemness markers in high-grade serous ovarian cancer, which were related to reduced response to conventional chemotherapy and lowered survival if expressed by treatment-naive tumors. The noted that, for targeting this cell population, EGFR, mTOR-PI3K and aurora kinase inhibitors may be candidates.